Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 3/20 | 0.50 |
| ▸ | CA1 | P00915 | 3/20 | 0.50 |
| ▸ | CA9 | Q16790 | 3/20 | 0.50 |
| ▸ | CA2 | P00918 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.48 |
| ▸ | MGLL | Q99685 | 6/20 | 0.48 |
| ▸ | PDK1 | Q15118 | 2/20 | 0.48 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.48 |
| ▸ | PDK3 | Q15120 | 2/20 | 0.48 |
| ▸ | PHGDH | O43175 | 2/20 | 0.48 |
| ▸ | FAAH | O00519 | 2/20 | 0.48 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21889229 | 0.82 | DPP4 (0.50) | CA12CA1CA9CA2ALDH1A1 | |
| SCHEMBL1986557 | 0.72 | — | — | |
| SCHEMBL9871267 | 0.72 | MGLL (0.49) | ALDH1A1MGLLPHGDHFAAHMAPT | |
| SCHEMBL10457653 | 0.71 | DPP4 (0.53) | ALDH1A1MGLLPHGDHFAAHSMN1; SMN2 | |
| SCHEMBL9749151 | 0.71 | SMN1; SMN2 (0.44) | CA12CA1CA9CA2ALDH1A1 | |
| SCHEMBL738198 | 0.71 | SMN1; SMN2 (0.54) | CA12CA1CA9ALDH1A1SMN1; SMN2 | |
| SCHEMBL1106416 | 0.71 | SMN1; SMN2 (0.44) | CA12CA1CA9CA2ALDH1A1 | |
| SCHEMBL12871099 | 0.71 | MGLL (0.53) | CA12CA1CA9CA2ALDH1A1 | |
| SCHEMBL14451159 | 0.70 | SMN1; SMN2 (0.58) | CA12CA1CA9CA2ALDH1A1 | |
| SCHEMBL14451158 | 0.70 | SMN1; SMN2 (0.58) | CA12CA1CA9CA2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210121397-A1 | BIODEGRADABLE INTRAVITREAL TYROSINE KINASE IMPLANTS | ALLERGAN INC (US) | 2021-04-29 | — | — | US | disclosed |
| US-10597421-B2 | Protected monomer and method of final deprotection for RNA synthesis | AGILENT TECHNOLOGIES, INC. (US) | 2020-03-24 | — | — | US | disclosed |
| US-20180186826-A1 | PROTECTED MONOMER AND METHOD OF FINAL DEPROTECTION FOR RNA SYNTHESIS | AGILENT TECHNOLOGIES, INC. | 2018-07-05 | — | — | US | disclosed |
| US-20180186826-A1 | PROTECTED MONOMER AND METHOD OF FINAL DEPROTECTION FOR RNA SYNTHESIS | AGILENT TECHNOLOGIES, INC. | 2018-07-05 | — | — | US | disclosed |
| US-9896472-B2 | Protected monomer and method of final deprotection for RNA synthesis | AGILENT TECHNOLOGIES, INC. (US) | 2018-02-20 | — | — | US | disclosed |
| US-9896472-B2 | Protected monomer and method of final deprotection for RNA synthesis | AGILENT TECHNOLOGIES, INC. (US) | 2018-02-20 | — | — | US | disclosed |
| US-20160199297-A1 | BIODEGRADABLE INTRAVITREAL TYROSINE KINASE IMPLANTS | ALLERGAN, INC. | 2016-07-14 | — | — | US | disclosed |
| US-9273086-B2 | Protected monomer and method of final deprotection for RNA synthesis | AGILENT TECHNOLOGIES, INC. (US) | 2016-03-01 | — | — | US | disclosed |
| US-9233070-B2 | Biodegradable intravitreal tyrosine kinase implants | ALLERGAN, INC. (US) | 2016-01-12 | — | — | US | disclosed |
| US-20160002282-A1 | Protected Monomer and Method of Final Deprotection for RNA Synthesis | AGILENT TECHNOLOGIES, INC. | 2016-01-07 | — | — | US | disclosed |
| US-20120258163-A1 | Tyrosine Kinase Microspheres | ALLERGAN, INC. | 2012-10-11 | — | — | US | disclosed |
| US-20120184724-A1 | PROTECTED MONOMERS AND METHODS OF DEPROTECTION FOR RNA SYNTHESIS | AGILENT TECHNOLOGIES, INC. (US) | 2012-07-19 | — | — | US | disclosed |
| US-20120184724-A1 | PROTECTED MONOMERS AND METHODS OF DEPROTECTION FOR RNA SYNTHESIS | AGILENT TECHNOLOGIES, INC. (US) | 2012-07-19 | — | — | US | disclosed |
| US-7771742-B2 | Producing eye insertable drug delivery agent; extruding active ingredient with polyvinyl alcohol free biodegradable polymer; pharmacokinetics | ALLERGAN, INC. (US) | 2010-08-10 | — | — | US | disclosed |
| US-7771742-B2 | Producing eye insertable drug delivery agent; extruding active ingredient with polyvinyl alcohol free biodegradable polymer; pharmacokinetics | ALLERGAN, INC. (US) | 2010-08-10 | — | — | US | disclosed |
| US-20100076183-A1 | PROTECTED MONOMER AND METHOD OF FINAL DEPROTECTION FOR RNA SYNTHESIS | AGILENT TECHNOLOGIES, INC. | 2010-03-25 | — | — | US | disclosed |
| US-20080260803-A1 | Producing eye insertable drug delivery agent; extruding active ingredient with polyvinyl alcohol free biodegradable polymer | ALLERGAN,INC. (US) | 2008-10-23 | — | — | US | disclosed |
| US-20080241252-A1 | METHODS AND COMPOSITIONS FOR INTRAOCULAR ADMINISTRATION TO TREAT OCULAR CONDITIONS | ALLERGAN, INC. (US) | 2008-10-02 | — | — | US | disclosed |
| US-20080241252-A1 | METHODS AND COMPOSITIONS FOR INTRAOCULAR ADMINISTRATION TO TREAT OCULAR CONDITIONS | ALLERGAN, INC. (US) | 2008-10-02 | — | — | US | disclosed |
| US-7414054-B2 | 3-(arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors | ALLERGAN, INC. (US) | 2008-08-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120258163-A1 | Tyrosine Kinase Microspheres | KDR, FLT1, DSTYK | CA12 4120/4885CA1 3838/4885CA9 2942/4885 |
| US-20210121397-A1 | BIODEGRADABLE INTRAVITREAL TYROSINE KINASE IMPLANTS | KDR, PTK2B, DSTYK | CA12 2609/4885CA1 2734/4885CA9 1607/4885 |
| US-20180186826-A1 | PROTECTED MONOMER AND METHOD OF FINAL DEPROTECTION FOR RNA SYNTHESIS | NSUN2, RNGTT, RNMT | CA12 4226/4885CA1 4111/4885CA9 4526/4885 |
| US-20100076183-A1 | PROTECTED MONOMER AND METHOD OF FINAL DEPROTECTION FOR RNA SYNTHESIS | RNGTT, RNMT, NSUN2 | CA12 4288/4885CA1 3756/4885CA9 3986/4885 |
| US-20160199297-A1 | BIODEGRADABLE INTRAVITREAL TYROSINE KINASE IMPLANTS | KDR, PTK2B, DSTYK | CA12 2584/4885CA1 2725/4885CA9 1590/4885 |
| US-10597421-B2 | Protected monomer and method of final deprotection for RNA synthesis | NSUN2, RNGTT, RNMT | CA12 4226/4885CA1 4111/4885CA9 4526/4885 |
| US-20160002282-A1 | Protected Monomer and Method of Final Deprotection for RNA Synthesis | NSUN2, SNRPB2, RNGTT | CA12 3061/4885CA1 4127/4885CA9 4286/4885 |
| US-20080241252-A1 | METHODS AND COMPOSITIONS FOR INTRAOCULAR ADMINISTRATION TO TREAT OCULAR CONDITIONS | FLT1, JAK1, KDR | CA12 2150/4885CA1 3278/4885CA9 752/4885 |
| US-20120184724-A1 | PROTECTED MONOMERS AND METHODS OF DEPROTECTION FOR RNA SYNTHESIS | RNMT, RNGTT, NSUN2 | CA12 3671/4885CA1 3185/4885CA9 4025/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.